Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
15 drugs in development
By Therapeutic Area
top 1
R&D Momentum
87/100
Pipeline Velocity
65/100
Trial Completion Rate
72/100
Pipeline Concentration
50/100
Pipeline Freshness
65/100
Strategic Signals
Activity
Last 14 days
Young Adult Infusion Space Survey: Comparing Experiences of Adolescents and Young Adults in Infusion Spaces at North Carolina Basnight Cancer Hospital
Population-Based Molecular Epidemiology of Breast Cancer, Carolina Breast Cancer Study, Phase 4
Keep Social Randomized Controlled Trial for Young Adults With Cancer
Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer
Tissue Procurement For Hematolymphoid Conditions
Designing and Evaluating Communication for Dual Users of E-cigarettes and Combustible Cigarettes
Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer
A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma
University of North Carolina Pleural Fluid Registry
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)